| Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angiotensin blockers. | |
| | |
MedLine Citation:
|
PMID: 16907653 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin (Ang) II plays important roles in the development of hypertension and cardiovascular and renal injury. Pharmaceutical approaches to block its activity led to the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Numerous trials have documented their efficacy in controlling blood pressure, minimising left ventricular remodelling, preventing progression to heart failure, ameliorating proteinuria and retarding renal disease progression. Although they are considered safe in general, there remain concerns about the potential for adverse events in certain target populations. Recently, several novel, low molecular weight renin inhibitors without the extended peptide-like backbone of previous renin inhibitors were developed with favourable pharmacokinetic properties. They have been shown to successfully reduce Ang II levels in normal volunteers and to lower blood pressure in patients with mild-to-moderate hypertension. In this review, the authors summarise current knowledge about these renin inhibitors. |
| | |
Authors:
|
Huifang Cheng; Raymond C Harris |
Related Documents
:
|
991543 - Neural factors contributing to renin release during reduction in renal perfusion pressu... 6400363 - Neuropeptides in cardiovascular control. 494223 - Hemodynamic changes after experimental reduction of the left atrium. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on drug safety Volume: 5 ISSN: 1744-764X ISO Abbreviation: Expert Opin Drug Saf Publication Date: 2006 Sep |
Date Detail:
|
Created Date: 2006-08-15 Completed Date: 2006-08-23 Revised Date: 2008-04-14 |
Medline Journal Info:
|
Nlm Unique ID: 101163027 Medline TA: Expert Opin Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 631-41 Citation Subset: IM |
Affiliation:
|
George M. O'Brien Kidney and Urologic Diseases Center and Division of Nephrology, Vanderbilt University School of Medicineand Nashville Veterans Affairs Hospital, Nashville, TN 37232, USA. huifang.cheng@vanderbilt.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Abnormalities, Drug-Induced
/
etiology Amides Angiotensin-Converting Enzyme Inhibitors / adverse effects, therapeutic use* Animals Clinical Trials as Topic Fumarates / adverse effects, therapeutic use Humans Hyperkalemia / chemically induced* Hypertension / drug therapy* Hypotension / chemically induced* Inappropriate ADH Syndrome / chemically induced Male Mice Receptors, Angiotensin / antagonists & inhibitors* Renin / antagonists & inhibitors*, physiology |
| Chemical | |
Reg. No./Substance:
|
0/Amides; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Fumarates; 0/Receptors, Angiotensin; 0/aliskiren; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiac dysfunction associated with trastuzumab.
Next Document: Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.